Login to Your Account

New Phase III Data Strong

Biogen Hemo Therapy Travels 'A-LONG' Pathway to Success

By Randy Osborne
Staff Writer

Monday, July 8, 2013

Last fall, when Biogen Idec Inc. and partner Swedish Orphan Biovitrum made public the Phase III from A-LONG, a trial testing their long-lasting recombinant factor VIII candidate – since branded Eloctate – in hemophilia A, most analysts were pleased but cautious.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription